David Gur ScD, Presenter: Nothing to Disclose

Jules Henry Sumkin DO, Abstract Co-Author: Scientific Advisory Board, Hologic, Inc

Margarita Louise Zuley MD, Abstract Co-Author: Research grant, Hologic, Inc

Maria Lena Anello MD, Abstract Co-Author: Nothing to Disclose

Victor J Catullo MD, Abstract Co-Author: Nothing to Disclose

Denise Chough MD, Abstract Co-Author: Nothing to Disclose

Cathy S Cohen MD, Abstract Co-Author: Nothing to Disclose

Marie Adele Ganott MD, Abstract Co-Author: Nothing to Disclose

Christiane Mary Hakim MD, Abstract Co-Author: Nothing to Disclose

William J Hoffman MD, Abstract Co-Author: Nothing to Disclose

Ratan Shah MD, Abstract Co-Author: Nothing to Disclose

Dilip Digambar Shinde MD, Abstract Co-Author: Nothing to Disclose

Report the preliminary results of an ongoing prospective clinical study that evaluates the impact of using digital breast tomosynthesis (DBT) during baseline screening mammography.

Under an institutional review board approved protocol, consenting women between 39 and 56 years of age scheduled for their baseline screening mammogram underwent both digital mammography (FFDM) and DBT at the same visit. The FFDM images (mode 1) and the FFDM images together with the DBT images (mode 2) were interpreted independently by two experienced radiologists under standard clinical screening protocol. A woman was recalled for a diagnostic workup if either radiologist recommended recall. This preliminary analysis reports the results from the first 120 participants in this prospective study. We assessed the proportion of recommended recalls (BIRADS 0 ratings) from clinical interpretations of FFDM alone and FFDM combined with DBT.

The fraction of women recommended for recall given to either or both breasts using FFDM alone and FFDM combined with DBT was 61/120 (50.8%) and 44/120 (36.7%), respectively. This represents is a 28% reduction in recall rate. Thirty five women (29%) were recalled by both modalities. The breast based proportion of BIRADS 0 using FFDM alone and FFDM combined with DBT was 78/240 (32.5%) and 49/240 (20.4%), respectively, and breast based recommendation agreement was observed in 173/240 ratings (72%). The reduction observed in recall rates to date is quite variable among the 13 readers participating in the study. To date, no cancers and three high risk biopsy proven cases were found. The three high risk cases were actually recalled under both modes. Laboratory (“study knowledge”) effect which results in higher than expected baseline recall rates is being investigated.

DBT in combination with FFDM  resulted in a substantial decrease in recall rates during baseline screening mammography of young women.

This preliminary observation from an ongoing prospective study demonstrates an actual and a substantial reduction in recall rates when including DBT during baseline screening.

Gur, D, Sumkin, J, Zuley, M, Anello, M, Catullo, V, Chough, D, Cohen, C, Ganott, M, Hakim, C, Hoffman, W, Shah, R, Shinde, D, Recall Rate Reduction with Tomosynthesis during Baseline Examinations: Preliminary Assessment from a Prospective Screening Trial.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11004417.html